Formosa Laboratories Executive and Leadership Team

Chih-Ping Yang, the Chief Executive Officer at Formosa Laboratories, directs the overarching corporate strategy and global market positioning. Overseeing all business units, Chih-Ping Yang ensures alignment with the company's mission to produce high-quality APIs and UV-filters. This leadership role involves navigating complex regulatory landscapes across Taiwan, the US, Germany, and Japan, maintaining the company's esteemed GMP compliance. By fostering innovation in process development and custom synthesis, Chih-Ping Yang drives Formosa Laboratories' capacity to serve diverse pharmaceutical needs from early-stage development through full commercial production. The Chief Executive Officer's strategic vision underpins the company's significant global market share in products like Vitamin D derivatives and essential UV-filters, solidifying Formosa Laboratories' reputation for reliability and advanced manufacturing capabilities.

C.Y. Cheng, the President at Formosa Laboratories, spearheads operational execution and manufacturing excellence. Managing the modern facilities near Taipei, C.Y. Cheng ensures the consistent production of a wide array of APIs, including critical Vitamin D derivatives and specialized compounds like Montelukast and Mycophenolate Mofetil. This role demands rigorous oversight of GMP compliance, maintaining approvals from key international bodies such as the US FDA and PMDA of Japan. C.Y. Cheng drives efficiency in the custom synthesis services, guiding projects from process development to full commercial output with comprehensive documentation support. The President's focus on operational integrity guarantees Formosa Laboratories' ability to meet global demand for its pharmaceutical ingredients and UV-filters, such as avobenzone and Octinoxate, reinforcing the company's position as a major world producer.

Chen-Yu Cheng, the President at Formosa Laboratories, focuses on expanding market reach and enhancing product portfolio development. Overseeing the strategic introduction of new APIs and UV-filters, Chen-Yu Cheng ensures Formosa Laboratories remains at the forefront of pharmaceutical innovation. This leadership position involves cultivating relationships with global regulatory agencies to maintain and expand GMP certifications, critical for market access in Taiwan, the US, Germany, and Japan. Chen-Yu Cheng drives the commercialization efforts for key products, including Balsalazide, Capsaicin, and Sevelamer, alongside the company's significant UV-filter offerings like avobenzone. The President's strategic initiatives support the growth of custom synthesis services, attracting clients seeking reliable process development and commercial production partners. Chen-Yu Cheng's market-focused leadership strengthens Formosa Laboratories' global presence and revenue streams.

C.P. Yang, the President at Formosa Laboratories, directs the company's research and development initiatives and technological advancements. Championing the development of novel APIs and UV-filters, C.P. Yang ensures Formosa Laboratories maintains a competitive edge in the global pharmaceutical landscape. This critical role involves overseeing the technical aspects of GMP compliance, collaborating with DOH of Taiwan, US FDA, and other international bodies to validate manufacturing processes. C.P. Yang guides the expansion of the custom synthesis division, focusing on complex chemical processes and documentation support for clients requiring specialized API production. The President's commitment to scientific rigor fuels the company's capacity to produce a diverse range of products, from Vitamin D derivatives to advanced UV-filters like Octinoxate. C.P. Yang's leadership in R&D solidifies Formosa Laboratories' reputation for technical expertise and product quality.